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Hepatitis C Virus Infection Among People Who Inject 
Drugs: The InC3 Collaboration
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for the International Collaboration of Incident HIV and HCV in Injecting Cohorts (InC3)
1Department of Epidemiology and Biostatistics, University of California, San Francisco; 2Centre Hospitalier de l'Universite de Montreal (CRCHUM), Université de Montréal, Quebec, Canada; 
3Department of Medicine, University of California, San Francisco; 4Burnet Institute, Melbourne, Australia; 5Department of Public Health and Epidemiology of Infectious Disease, Academic Medical 
Center, Amsterdam, The Netherlands; 6Department of Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland; 7Kirby Institute, University of New South Wales, Sydney, Australia; 
8Department of Medicine, Massachusetts General Hospital, Boston; 9School of Medical Sciences, University of New South Wales, Sydney, Australia; and 10Department of Internal Medicine, 
University of New Mexico Health Center, Albuquerque
Background. We determined temporal trends (1985–2011) in hepatitis C virus (HCV) incidence and associated behavioral 
exposures for people who inject drugs (PWID) from the United States (Boston, Baltimore, and San Francisco), Canada (Montreal), 
the Netherlands (Amsterdam), and Australia (Sydney and Melbourne).
Methods. Using population-based cohort data from HCV-negative PWID, we calculated overall and within-city HCV incidence 
trends, HCV rates by study enrollment period (1985–2011), and temporal trends in exposure behaviors. Poisson regression models 
estimated trends in HCV incidence over calendar-time. Survival models identified risk factors for HCV incidence across cities and 
estimated independent effects of city and calendar period on HCV infection risk.
Results. Among 1391 initially HCV-negative participants followed prospectively (1644.5 person-years of observation [PYO]), 
371 HCV incident infections resulted in an overall incidence of 22.6 per 100 PYO (95% confidence interval [CI], 20.4–25.0). Incidence 
was highest and remained elevated in Baltimore (32.6/100 PYO), San Francisco (24.7/100 PYO), and Montreal (23.5/100 PYO), low-
est in Melbourne and Amsterdam (7.5/100 PYO and 13.1/100 PYO, respectively), and moderate (21.4/100 PYO) in Sydney. Higher 
rates of syringe and equipment sharing and lower prevalence of opioid agonist therapy were associated with HCV incidence in cities 
with the highest incidence. Risk for infection dropped by 18% for every 3-year increase in calendar-time (adjusted hazard ratio, 0.8 
[95% CI, .8–.9]) in the multivariable model.
Conclusions. Differences in prevention strategies and injecting contexts may explain the ongoing high HCV incidence in these 
North American cities and emphasize the need for scale-up of opioid agonist therapy and increased coverage of needle and syringe 
programs in North America.
Keywords. hepatitis C virus (HCV); incidence trends; epidemiology; people who inject drugs; harm reduction strategies.
More than 10 million people who inject drugs (PWID) live 
with chronic hepatitis C virus (HCV) infection globally, and 
HCV prevalence is estimated to be between 10% and 90% in 
this population [1, 2]. Injection drug use continues to be the 
major mode of HCV transmission in high- and middle-in-
come countries since the implementation of effective blood 
supply screening in the early 1990s [3]. To date, meta-analyses 
and systematic reviews of HCV have focused on prevalence, 
with analyses of data from the same studies [1, 4, 5]. Only 2 
meta-studies included HCV incidence estimates, and no prior 
studies compared HCV incidence across geographic regions or 
time periods [6, 7]. Robust data on HCV incidence are essen-
tial for describing disease etiology and developing effective 
public health responses, including prevention and treatment.
Longitudinal studies enable the observation and analysis of HCV 
transmission trends over time and produce insights into drivers of 
the epidemic. The International Collaboration of Incident HIV and 
HCV in Injecting Cohorts (InC3) study brings together well-char-
acterized longitudinal cohorts of PWID in the United States 
(Boston, Baltimore, and San Francisco), Canada (Montreal), the 
Netherlands (Amsterdam), and Australia (Sydney and Melbourne) 
[8] (https://ctsc.health.unm.edu/apps/inc3/). Each cohort system-
atically collected prospective serologic and behavioral data from 
HCV antibody–negative PWID recruited from the community, 
and together, span >2 decades (1985–2011). City-level differences 
in harm reduction policies and intervention coverage are difficult 
to directly measure. We leveraged epidemiological data collected at 
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the individual level to (1) estimate overall incidence of HCV infec-
tion and temporal (1985–2011) trends in incidence; (2) examine 
behavioral predictors of HCV infection; and (3) describe and com-
pare temporal trends in injecting exposures within a subset of InC3 
cities (Baltimore, San Francisco, Montreal, Sydney, Amsterdam, 
and Melbourne). This study provides findings on HCV etiology 
and inferences about drivers of infection trends within a high-in-
come country context, globally.
METHODS
Study Population
Participants were selected from pooled epidemiological data 
collected from prospective cohort studies in Baltimore [9], San 
Francisco [10], Montreal [11], Sydney [12, 13], Amsterdam 
[14], and Melbourne [15]. Study eligibility criteria required 
PWID to be HCV antibody (anti-HCV) negative and HCV 
RNA negative at enrollment, with at least 1 follow-up serologic 
visit, and to self-report recent injection drug use (Table 1). Two 
InC3 cohorts (Boston Boston Acute HCV Study: Transmission, 
Immunity, and Outcome Network (BAHSTION) cohort and 
the Sydney Australian Trial in Acute Hepatitis C (ATAHC) 
cohort) were excluded because only participants with acute or 
early (within 2 years of exposure) HCV infection were enrolled. 
A third InC3 cohort (Australian HITS-p cohort) recruited 
from prisons, rather than community samples, and thus was 
excluded [8].
Table 1. Summary of Inclusion and Study Procedures Applicable to Study Analysis
Cohort Name City Sample Size Inclusion Criteria No. of Sites
Recruitment 
Method(s)
Enrollment 
Perioda
Follow-up Interval for 
Serologyb
Amsterdam Cohort 
Studies (ACS)
Amsterdam 48 Active drug users 
(both PWID and 
non-PWID) using 
hard drugs at least 
3 times/wk; ≥18 y 
of age; HIV negative 
and anti-HCV 
negative
1 Community-based 
outreach; open 
enrollment
1984–present 4-mo intervals (until 
2003) then 6-mo 
intervals
Baltimore Before and 
After Acute Study in 
Hepatitis (BBAASH)c
Baltimore 288 Active PWID aged 
18–65 y; anti-HCV 
negative
1 Community-based 
outreach; open 
enrollment
1996–present Monthly
Networks Study (N2) Melbourne 199 Injection drug use 
in past 6 mo; 
≥18 years of age; 
anti-HCV negative
6 Community- 
based outreach 
and respon-
dent-driven 
sampling; open 
enrollment
2005–2012 3-mo intervals
St Luc Cohort 
(HEPCO)
Montreal 244 Injection drug use in 
past 6 mo; ≥14 y 
of age; anti-HCV 
negative
1 Community-based 
outreach; open 
enrollment
2004–present 3–6-mo intervals
The UFO Study (UFO) San Francisco 398 Injection drug use in 
past mo; <30 y of 
age at enrollment; 
anti-HCV negative
1 Community-based 
outreach; open 
enrollment
2000–present Monthly
Hepatitis C Virus 
Cohort (CU)
Sydney 257 Injection drug use 
within the past 
6 mo; anti-HCV 
negative
3 Community-based 
outreach; open 
enrollment
1999–2002 3–6-mo intervals
Hepatitis C Incidence 
and Transmission 
Study- Community 
(HITS-c)
Sydney 134 Injection drug use 
within past 12 mo; 
≥16 y of age; anti- 
HCV negative
5 Community-based 
outreach; open 
enrollment
2008–2012 3-, 6-, 9-, 12-, 15-, 18-, 
24-mo intervals
All cohorts enrolled participants prospectively.
Abbreviations: anti-HCV, hepatitis C virus antibody; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PWID, people who inject drugs.
aAs of March 2015.
bAntibody and RNA testing were performed at the time of acute HCV detection. Anti-HCV testing was performed using the following assays: HCV enzyme immunoassay (EIA) 2.0 (Abbott 
Laboratories, Abbott Park, Illinois), EIA-3 (Ortho Clinical Diagnostics, Raritan, New Jersey), or Abbott Architect anti-HCV. Very little difference in antibody detection has been demonstrated 
between HCV EIA 2.0 and 3.0 [18]. Qualitative HCV RNA testing was performed using the following assays: Versant TMA (Bayer, Australia; <10 IU/mL), COBAS AmpliPrep/COBAS TaqMan 
(Roche, Branchburg, New Jersey; <15 IU/mL), COBAS Amplicor HCV Test v2.0 (Roche Diagnostics, Mannheim, Germany; <50 IU/mL), or discriminatory HCV transcription-mediated ampli-
fication component of the Procleix HIV-1/HCV (Gen-Probe, San Diego, California; <12 copies/mL). Quantitative HCV RNA testing was performed using the Versant HCV RNA 3.0 (Bayer; 
<615 IU/mL), COBAS Amplicor HCV Monitor 2.0 (Roche Diagnostics; <600 IU/mL), COBAS AmpliPrep/COBAS TaqMan (Roche; <15 IU/mL), or an in-house polymerase chain reaction 
(<1000 IU/mL).
cBBAASH recruits and monitors young PWID for HCV infection, with a focus on serological data to assess the clinical characteristics of acute infection and reinfection. Because research 
goals focus on understanding questions related to immunology and virology, behavioral data were not systematically collected between 2000 and 2012. The BBAASH data server was 
compromised in 2005, leading to the loss of data on age and biological sex for some participants. Investigators preformed genome-wide association studies to obtain sex for participants 
who acquired HCV infection, but because age is not a genetic trait, age information was not recovered.
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Data Collection and Procedures
Cohorts systematically collected self-reported data on sociode-
mographic characteristics, injecting behaviors, and serological 
data on anti-HCV and HCV RNA. All cohorts also provided 
loss-to-follow-up data.
HCV Testing
HCV testing methods varied by cohort, including anti-HCV, 
HCV RNA, and genotype testing, but were consistent within 
each site (Figure 1). The majority of HCV tests occurred during 
regular study data collection periods, with some retrospective 
testing on frozen serum or plasma specimens to fill in data gaps.
HCV Infection Outcome
In this analysis, primary HCV incident infection (hereafter 
referred to as HCV incident infection) was defined as either 
(1) positive anti-HCV and HCV RNA positive, or (2) posi-
tive HCV RNA test following a previously documented nega-
tive anti-HCV and HCV RNA test (Figure  1). Because a few 
cohorts stopped following participants at the 24-month mark 
(Baltimore and Sydney), we censored the follow-up period of all 
participants eligible for this analysis at 24 months.
The date of HCV infection was estimated as either (1) the 
midpoint between the last negative and first positive anti-HCV 
test dates for those defined as having anti-HCV seroconver-
sion, or (2) the date of the first HCV RNA–positive visit minus 
28 days for those whose infection was identified via an RNA-
positive/anti-HCV–negative test [16]. The median duration of 
observed time to incident HCV was 12 months (interquartile 
range [IQR], 6–20).
Statistical Analyses
To examine potential bias due to differential loss to follow-up, 
we used Pearson χ2 or Kruskal-Wallis tests to compare distribu-
tions of selected demographic and injecting risk behavior vari-
ables between participants with follow-up visits and those with 
only baseline visits.
We used descriptive analyses to characterize the study pop-
ulation overall and by city (Baltimore, San Francisco, Montreal, 
Sydney, Amsterdam, and Melbourne). Primary analyses employed 
life-table methods to construct HCV incidence curves by city and 
calculate HCV infection rates within the first 24 months of fol-
low-up (presented as rates per 100 person-years of observation 
[PYO] with 95% confidence intervals [CIs]). Next, we conducted 
analyses to describe overall and within-city HCV incidence trends. 
To compare HCV infection rates across cities, we used Kaplan-
Meier estimates and log-rank tests (see Supplementary Figure 1). 
The same approach was used to compare HCV rates by period of 
study enrollment (1985–1990 and in 3-year intervals from 1991 to 
2011) across cities. We used Poisson regression to test for the trend 
in HCV incidence over calendar-time (presented as incidence rate 
ratios [IRRs] per 3-year intervals and 95% CIs).
We fit bivariate Poisson regression models to examine possi-
ble explanations for differences in HCV incidence trends across 
cities. Next, using self-reported data collected at enrollment, we 
plotted temporal trends in the proportion of persons reporting 
the following recent injecting behaviors: (1) main or most fre-
quent/often illicit drug injected (heroin, methamphetamine/
amphetamine, cocaine, other opiates (ie, prescription opioids), 
or heroin and cocaine in combination); (2) receptive syringe 
sharing (RSS) (yes/no); (3) opioid agonist therapy (OAT), 
including methadone and buprenorphine (yes/no); and (4) 
access to sterile syringes through safe sources (needle syringe 
program, chemist/pharmacist, vending machine, mobile out-
reach) (yes/no). Supplementary Table  1 provides details on 
time frames for risk factor measures by cohort. Proportions 
were calculated for 1985–1990 and 3-year intervals from 1991 
to 2011. Analyses did not include time-varying covariates due 
to variability in follow-up intervals and data availability. Last, 
we fit a stratified multivariable Cox propositional hazards 
model, allowing unique baseline hazards by city, to assess the 
independent relationship between recent RSS, OAT, and cal-
endar-time with risk for HCV incidence, while controlling 
for biological sex, age, and city. Sensitivity analyses assessed 
multivariable model fit and main effects when Baltimore was 
included (Supplementary Table 2). All analyses were performed 
using Stata software version 13.0 (College Station, Texas).
RESULTS
General Characteristics
In total, 827 HCV-negative participants did not complete fol-
low-up visits. These participants were not significantly different 
from those with at least 1 follow-up visit with respect to biological 
Figure 1. Participant inclusion flowchart. Abbreviations: HCV, hepatitis C virus; 
InC3, International Collaboration of Incident HIV and HCV in Injecting Cohorts.
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sex, ethnicity, main or most frequent drug injected, frequency of 
injection, recent OAT, and history of incarceration. However, par-
ticipants lost to follow-up were significantly younger (mean age, 
23 vs 26 years; P ≤ .001), more educated (53% vs 41% completed 
secondary school; P ≤. 001), and more likely to report RSS (40% 
vs 19%; P ≤. 001) than those who were retained. Supplementary 
Table 3 details loss to follow-up rates by city.
Of the 1391 persons included in this study, 49% were in the 
United States, 18% in Canada, 30% in Australia, and 3% in the 
Netherlands. Overall, 64% were male, and the median age at 
enrollment was 25  years (IQR, 21–29  years). The most fre-
quently injected drug at baseline was heroin (53%), followed by 
meth/amphetamine (21%), cocaine (13%), other opiates (8%), 
and heroin and cocaine in combination (4%); Baltimore did 
not collect data on drug use. Table 2 shows all participant char-
acteristics, including loss to follow-up, at enrollment by city.
HCV Incidence: Overall, Geographic, and Temporal Trends
Overall Incidence
Over 1644.5 PYO, 371 persons had a HCV incident infection 
for an overall estimated incidence of 22.6/100 PYO (95% CI, 
20.4–25.0). Approximately one-half (n = 187) of incident infec-
tions were identified via an RNA-positive test. Overall, inci-
dence decreased from 24.6/100 PYO (95% CI, 21.8–27.8) in the 
first year of observation to 18.8/100 PYO (95% CI, 15.5–22.7) 
during the second study year. Compared with Melbourne, 
which had the lowest incidence rate of HCV (7.5/100 PYO 
[95% CI, 4.6–12.3/100 PYO]), IRRs were significantly elevated 
for Baltimore (IRR, 1.89 [95% CI, 1.1–3.14]), San Francisco 
(IRR, 2.6 [95% CI, 1.5–4.4]), Montreal (IRR, 2.6 [95% CI, 
1.5–4.4]), and Sydney (IRR, 2.2 [95% CI, 1.3–3.8]). Incidence 
in Amsterdam was not significantly elevated compared with 
Melbourne (IRR, 1.6 [95% CI, .7–3.6]). Table 2 describes overall 
HCV incidence rates by city.
Temporal Trends in HCV Incidence
We observed differences in the magnitude and direction of 
HCV incidence trends across cities (Figure  2). In Baltimore, 
HCV incidence was initially very high at 45.1/100 PYO dur-
ing 1997–1999, but then significantly declined to 20.1/100 
PYO during 2009–2011 (IRR, 0.7 per 3 years [95% CI, .6–.9]) 
(Figure  2A). In San Francisco, incidence was 23.4/100 PYO 
during 2000–2002, remaining high and relatively constant 
across calendar-time with an increase to 30.8/100 PYO during 
2009–2011 (IRR, 1.0 [95% CI, .8–1.2]). In Montreal, incidence 
remained high (range, 20.9–26.6) across 2003–2011 (IRR, 
1.1 [95% CI, .8–1.6]). In Sydney, incidence was high during 
the early 2000s (33.4/100 PYO) with a statistically significant 
decline in 2009–2011 (9.9/100 PYO) (IRR, 0.7 [95% CI, .6–.8]). 
In Amsterdam, incidence was initially high during 1986–1993, 
but quickly declined to 9.0/100 PYO during 1994–1996 with no 
new infections identified in subsequent years (IRR, 0.4 [95% CI, 
.3–.8]). Last, in Melbourne, incidence was low and remained 
low across all years (IRR, 0.8 [95% CI, .4–1.5]).
Geographical Differences in Behaviors/Characteristics
Table 2 displays HCV incidence estimates by demographic and 
behavioral variables for each city.
Temporal Trends in Injection-Related Exposures
To further contextualize observed differences in HCV incidence 
trends across cities, Figure 3 illustrates temporal trends in the 
most frequent drug injected, recent RSS, recent OAT use, and 
recent access to sterile syringes through safe sources reported 
at enrollment. For San Francisco, where the majority of persons 
were injecting heroin, levels of RSS remained between 35% and 
43%, with few (8%–12%) reporting recent OAT across all time 
periods. In Montreal, cocaine was the most frequently injected 
drug in the 2003–2005 period, but by 2009–2011 had declined 
and was primarily superseded by “other opiates.” Additionally, 
consistent levels (36%–38%) of RSS and OAT (19%–37%) were 
observed. In Sydney, reports of heroin as the most frequent 
drug injected were varying (53%–95%) over time, with meth-
amphetamine injecting increasing from 4% to 40% from 2000 
to 2008; a sharp decline in the prevalence of RSS from 39% in 
2000–2002 to 7% in 2009–2011 was coupled with increasing lev-
els (34%–60%) of OAT. In Amsterdam, levels of heroin injection 
fluctuated across 1994–2008, with levels of methamphetamine 
injection steadily increasing from 5% during 1994–1999 to 38% 
in 2006–2008; RSS declined as OAT levels increased from 3% in 
1994–1996 to almost 100% in 2009–2011. In Melbourne, during 
2003–2011, the majority of individuals reported injecting her-
oin, and RSS levels decreased from 20% to 11%; levels of OAT 
were consistent (42%–58%). Obtaining sterile syringes from 
needle syringe provision (NSP), pharmacies, vending machines, 
or through outreach was high (>80%) across all time periods 
and in all cities, with the exception of Sydney, where access levels 
increased from 50% in 2000–2002 to 90% in 2009–2011.
Independent Differences in Risk for HCV Incidence
After adjusting for age, biological sex, and city, recent RSS 
was independently associated with an elevated risk for HCV 
infection (adjusted hazard ratio [aHR], 1.5 [95% CI, 1.2–2.0]), 
whereas recent OAT use reduced risk (aHR, 0.5 [95% CI, 
.4–.7]). Risk of infection dropped by approximately 18% for 
every 3-year increase in calendar-time (aHR, 0.7 [95% CI, 
.6–.8]). No significant effect was observed for biological sex or 
age at enrollment (Table 3).
DISCUSSION
To our knowledge, this is the first multicity study of trends in 
HCV incidence and injecting behavior over the past 25 years. 
Overall HCV incidence was high (21.5/100 PYO), and the risk 
864 • CID 2017:64 (1 April) • Morris et al
Ta
bl
e 
2.
 
Fr
eq
ue
nc
ie
s 
an
d 
H
ep
at
iti
s 
C 
Vi
ru
s 
In
ci
de
nc
e 
Es
tim
at
es
 fo
r B
as
el
in
e 
Ch
ar
ac
te
ri
st
ic
s 
by
 C
ity
 (N
 =
 1
39
1)
C
ha
ra
ct
er
is
tic
B
al
tim
or
e 
(n
 =
 2
88
)
S
an
 F
ra
nc
is
co
 (n
 =
 3
98
)
M
on
tr
ea
l (
n 
=
 2
44
)
Sy
dn
ey
 (n
 =
 2
94
)
A
m
st
er
da
m
 (n
 =
 4
8)
M
el
bo
ur
ne
 (n
 =
 1
19
)
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
O
ve
ra
ll 
H
C
V
 in
ci
de
nc
e
10
8 
(3
7)
32
.6
 (2
6.
8–
39
.8
)
13
7 
(3
4)
24
.7
 (2
0.
4–
29
.9
)
94
 (3
8)
23
.5
 (1
8.
8–
29
.4
)
66
 (2
2)
21
.4
 (1
6.
7–
27
.3
)
17
 (3
5)
13
.1
 (7
.0
–2
4.
3)
32
 (2
7)
7.
5 
(4
.6
–1
2.
3)
M
ed
ia
n 
N
o.
 o
f 
st
ud
y 
 
vi
si
ts
 (I
Q
R
)
13
 (5
–2
3)
…
4 
(3
–7
)
…
8 
(4
–1
5)
…
4 
(2
–5
)
…
17
 (5
–2
9)
…
4 
(3
–8
)
…
Lo
ss
 t
o 
fo
llo
w
-u
p 
be
fo
re
 
24
 m
o 
(n
 =
 1
02
0)
11
2 
(5
9)
…
20
1 
(6
8)
…
61
 (3
6)
…
18
1 
(7
8)
…
9 
(2
4)
…
39
 (3
8)
…
B
io
lo
gi
ca
l s
ex
 
M
al
e
14
1 
(4
9)
41
.5
 (3
2.
0–
54
.0
)
26
5 
(6
7)
22
.2
 (1
7.
5–
29
.3
)
19
7 
(8
1)
24
.6
 (1
9.
3–
31
.3
)
20
0 
(6
8)
24
.6
 (1
9.
3–
31
.3
)
35
 (7
3)
14
.6
 (7
.3
–2
9.
3)
78
 (6
6)
9.
2 
(5
.3
–1
5.
8)
 
Fe
m
al
e
78
 (2
7)
60
.0
 (4
4.
3–
81
.0
)
13
3 
(3
3)
30
.4
 (2
2.
2–
41
.6
)
47
 (1
9)
19
.0
 (1
0.
8–
33
.4
)
94
 (3
2)
19
.0
 (1
0.
8–
33
.4
)
13
 (2
7)
9.
2 
(2
.3
–3
6.
6)
41
 (3
5)
4.
2 
(1
.4
–1
3.
0)
 
U
nk
no
w
na
69
 (2
4)
1.
0 
(0
.1
–7
.2
)
0
…
0 
(0
)
…
0 
(0
)
…
0 
(0
)
…
0 
(0
)
…
M
ed
ia
n 
ag
e,
 y
 (I
Q
R
)
25
 (2
3–
29
)
22
 (2
0–
26
)
31
 (2
6–
39
)
24
 (2
0–
28
)
27
 (2
4–
31
)
25
 (2
2–
28
)
E
du
ca
tio
n 
le
ve
l
 
H
ig
h 
sc
ho
ol
 o
r 
be
lo
w
0 
(0
)
…
17
3 
(4
4)
25
.7
 (1
9.
6–
33
.7
)
64
 (2
6)
29
.0
 (1
9.
4–
43
.2
)
11
7 
(4
0)
29
.0
 (1
9.
4–
43
.2
)
3 
(6
)
…
31
 (2
6)
3.
1 
(0
.8
–1
2.
3)
 
C
om
pl
et
ed
 h
ig
h 
sc
ho
ol
  
 
or
 a
bo
ve
0 
(0
)
…
21
9 
(5
5)
22
.4
 (1
6.
9–
29
.7
)
18
0 
(7
4)
21
.7
 (1
6.
5–
29
.3
)
17
7 
(6
0)
21
.7
 (1
6.
5–
28
.3
)
0 
(0
)
…
16
 (1
3)
5.
8 
(1
.5
–2
3.
4)
 
U
nk
no
w
na
28
8 
(1
00
)
…
6 
(1
)
…
0 
(0
)
…
0 
(0
)
…
45
 (9
4)
…
72
 (6
1)
10
.6
 (6
.0
–1
8.
6)
E
th
ni
ci
ty
 
W
hi
te
/ C
au
ca
si
an
14
7 
(5
1)
…
29
8 
(7
5)
25
.7
 (2
0.
8–
31
.9
)
22
0 
(9
0)
24
.1
 (1
9.
1–
30
.4
)
21
8 
(7
4)
24
.1
 (1
9.
1–
30
.4
)
39
 (8
1)
12
.6
 (6
.3
–2
5.
2)
94
 (7
9)
5.
9 
(3
.2
–1
1.
1)
 
B
la
ck
/A
fr
ic
an
39
 (1
4)
…
33
 (8
)
20
.2
 (9
.6
–4
2.
3)
2 
(1
)
40
.2
 (5
.7
–2
85
.6
)
54
 (1
8)
40
.2
 (5
.7
–2
85
.6
)
0 
(0
)
…
16
 (1
3)
17
.3
 (7
.2
–4
1.
1)
 
In
di
ge
no
us
/ N
at
iv
e 
 
 
A
m
er
ic
an
0 
(0
)
…
9 
(2
)
20
.8
 (5
.2
–8
3.
3)
8 
(3
)
26
.4
 (6
.6
–1
05
.6
)
13
 (4
)
26
.4
 (5
.6
–1
05
.6
)
0 
(0
)
…
6 
(5
)
…
 
M
ix
ed
 o
r 
ot
he
r
2 
(1
)
…
52
 (1
3)
24
.0
 (1
3.
9–
42
.2
)
6 
(2
)
23
.5
 (5
.9
–9
3.
9)
7 
(2
)
23
.5
 (5
.9
–9
3.
9)
5 
(1
0)
13
.2
 (1
.9
–9
3.
8)
0 
(0
)
…
 
U
nk
no
w
na
10
0 
(4
5)
…
6 
(1
)
…
8 
(3
)
7.
0 
(1
.0
–4
9.
9)
2 
(1
)
…
4 
(8
)
18
.5
 (2
.6
–1
31
.4
)
3 
(3
)
21
.7
 (3
.1
–1
54
.0
)
H
is
to
ry
 o
f 
pr
is
on
 s
en
te
nc
e
 
N
o
0 
(0
)
…
79
 (2
0)
22
.1
 (1
4.
1–
34
.6
)
64
 (2
6)
21
.1
 (1
3 
.3
–3
3 
.5
)
78
 (2
7)
13
.8
 (8
.0
–2
3.
8)
0 
(0
)
…
87
 (7
3)
8.
4 
(4
.9
–1
4.
5)
 
Ye
s
0 
(0
)
…
31
6 
(8
0)
24
.6
 (1
9.
8–
30
.5
)
18
0 
(7
3)
24
.4
 (1
8 
.9
–3
1 
.4
)
56
 (1
9)
4.
5 
(1
.5
–1
3.
9)
20
 (4
2)
2.
6 
(0
.4
–1
8.
6)
32
 (2
7)
5.
1 
(1
.6
–1
5.
8)
 
U
nk
no
w
na
28
8 
(1
00
)
…
3 
(<
1)
…
0 
(0
)
…
16
0 
(5
4)
34
.7
 (2
6.
2–
46
.1
)
28
 (5
8)
23
.5
 (1
2.
2–
45
.2
)
0 
(0
)
…
R
ec
en
t 
un
st
ab
le
 h
ou
si
ng
 
N
o
0 
(0
)
…
59
 (1
5)
17
.6
 (9
.2
–3
3.
8)
91
 (3
7)
18
.6
 (1
2.
4–
27
.8
)
10
0 
(3
4)
9.
0 
(5
.0
–1
6.
3)
26
 (5
4)
7.
0 
(2
.3
–2
1.
8)
76
 (6
3.
9)
7.
93
 (4
.4
–1
4.
3)
 
Ye
s
0 
(0
)
…
32
9 
(8
2.
7)
24
.9
 (2
0.
3–
30
.6
)
15
3 
(6
2.
7)
26
.7
 (2
0.
4–
35
.0
)
19
4 
(6
6)
30
.0
 (
22
.9
–3
9.
2)
17
 (3
5.
4)
6.
7 
(1
.7
–2
6.
7)
43
 (3
6.
1)
6.
6 
(2
.8
–1
6.
2)
 
U
nk
no
w
na
28
8 
(1
00
)
…
10
 (2
)
…
0 
(0
)
…
0 
(0
)
…
5 
(1
0)
…
0 
(0
)
…
R
ec
en
t 
un
em
pl
oy
m
en
t
 
N
o
0 
(0
)
…
94
 (2
4)
25
.4
 (1
6.
9–
38
.2
)
15
3 
(6
3)
26
.3
 (2
0.
0–
34
.5
)
77
 (2
6)
28
.5
 (1
8.
2–
44
.6
)
0 
(0
)
…
49
 (4
1)
3.
5 
(1
.1
–1
0.
7)
 
Ye
s
0 
(0
)
…
28
6 
(7
2)
23
.9
 (1
9.
1–
30
.0
)
72
 (3
0)
15
.7
 (9
.8
–2
5.
3)
83
 (2
8)
40
.6
 (2
8.
2–
58
.4
)
0 
(0
)
…
69
 (5
8)
11
.3
 (6
.6
–1
9.
5)
 
U
nk
no
w
na
28
8 
(1
00
)
…
19
 (5
)
32
.9
 (1
5.
7–
69
.0
)
19
 (8
)
37
.1
 (1
8.
5–
74
.1
)
13
4 
(4
6)
9.
6 
(6
.1
–1
6.
2)
48
 (0
)
…
1 
(<
1)
…
H
IV
 s
ta
tu
s
 
Po
si
tiv
e
0 
(0
)
7 
(2
)
20
.4
 (5
.1
–8
1.
6)
1 
(1
)
…
0 
(0
)
…
0 
(0
)
…
0 
(0
)
…
 
N
eg
at
iv
e
0 
(0
)
26
5 
(6
7)
23
.7
 (1
8.
8–
29
.9
)
24
1 
(9
8)
23
.3
 (1
8.
6–
29
.2
)
13
4 
(4
6)
10
.0
 (6
.1
–1
6.
2)
35
 (7
3)
5.
0 
(1
.6
–1
5.
6)
67
 (5
6)
8.
4 
(4
.4
–1
6.
2)
 
U
nk
no
w
na
28
8 
(1
00
)
…
12
6 
(3
1)
27
.5
 (1
9.
6–
38
.7
)
2 
(1
)
84
.4
 (1
1.
9–
59
8.
8)
16
0 
(5
4)
24
.9
 (1
9.
0–
32
.5
)
13
 (2
7)
41
.5
 (1
9.
8–
87
.2
)
52
 (4
4)
6.
6 
(3
.2
–1
3.
9)
M
ed
ia
n 
(IQ
R
) d
ur
at
io
n 
of
 
in
je
ct
io
n 
dr
ug
 u
se
, y
4 
(1
–7
)
7 
(3
–1
3)
4 
(2
–8
)
4 
(1
–8
)
6 
(3
–1
0)
 
≤2
 y
0 
(0
)
…
10
5 
(2
6)
24
.3
 (1
6.
7–
35
.5
)
34
 (1
4)
35
.3
 (2
0.
9–
59
.5
)
58
 (2
0)
35
.3
 (2
0.
9–
59
.5
)
17
 (3
5)
19
.9
 (8
.3
–4
7.
7)
14
 (1
2)
13
.7
 (4
.4
–4
2.
5)
Geotemporal HCV Trends Among PWID • CID 2017:64 (1 April) • 865
C
ha
ra
ct
er
is
tic
B
al
tim
or
e 
(n
 =
 2
88
)
S
an
 F
ra
nc
is
co
 (n
 =
 3
98
)
M
on
tr
ea
l (
n 
=
 2
44
)
Sy
dn
ey
 (n
 =
 2
94
)
A
m
st
er
da
m
 (n
 =
 4
8)
M
el
bo
ur
ne
 (n
 =
 1
19
)
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
N
o.
 (%
)
IR
 
>
2 
y
0 
(0
)
…
29
3 
(7
3)
24
.8
 (1
9.
9–
31
.0
)
21
0 
(8
6)
21
.9
 (1
7.
1–
28
.0
)
23
6 
(8
0)
21
.9
 (1
7.
1–
28
.0
)
31
 (6
5)
9.
7 
(4
.1
–2
3.
4)
10
4 
(8
7)
7.
2 
(4
.2
–1
2.
4)
D
ru
g 
in
je
ct
ed
 m
os
t 
of
te
n
…
 
H
er
oi
n
0 
(0
)
…
21
4 
(5
4)
27
.4
 (2
1.
2–
35
.6
)
68
 (2
8)
12
.4
 (7
.0
–2
1.
8)
20
3 
(6
9)
25
.3
 (
18
.7
–3
4.
1)
18
 (3
8)
17
.9
 (7
.5
–4
3.
1)
76
 (6
4)
8.
3 
(4
.6
–1
5.
0)
 
A
m
ph
et
am
in
e/
  
 
m
et
ha
m
ph
et
am
in
e
0 
(0
)
…
12
6 
(3
2)
17
.5
 (1
1.
8–
25
.9
)
1 
(1
)
…
70
 (2
4)
7.
8 
(3
.4
–1
7.
3)
5 
(1
0)
…
19
 (1
6)
10
.4
 (3
.4
–3
2.
0)
 
C
oc
ai
ne
0 
(0
)
…
9 
(2
)
16
.4
 (4
.1
–6
5.
5)
12
1 
(4
9)
19
.3
 (
13
.5
–2
7.
6)
6 
(2
)
56
.9
 (3
1.
5–
10
2.
8)
5 
(1
0)
12
.0
 (1
.7
–8
5.
5)
1 
(1
)
…
 
O
th
er
 o
pi
at
es
0 
(0
)
…
3 
(1
)
32
.7
 (4
.6
–2
32
.1
)
50
 (2
1)
51
.3
 (
34
.4
–7
6.
6)
14
 (5
)
6.
6 
(0
.9
–4
6.
8)
0 
(0
)
…
20
 (1
7)
5.
5 
(1
.4
–2
2.
0)
 
H
er
oi
n 
+
 c
oc
ai
ne
  
 
(c
om
bi
ne
d)
0 
(0
)
…
28
 (7
)
35
.3
 (1
9.
6–
63
.8
)
5 
(2
)
…
0 
(0
)
…
17
 (3
5)
16
.1
 (6
.1
–4
3.
0)
0 
(0
)
…
 
U
nk
no
w
na
28
8 
(1
00
)
…
18
 (4
)
…
6 
(2
)
38
.7
 (2
1.
4–
69
.8
)
1 
(<
1)
12
.6
 (7
.4
–2
1.
2)
3 
(6
)
…
3 
(2
)
…
R
ec
en
t 
re
ce
pt
iv
e 
sy
rin
ge
 s
ha
rin
g
 
N
o
0 
(0
)
…
23
1 
(5
8)
18
.4
 (
14
.0
–2
4.
3)
16
6 
(6
8)
22
.5
 (1
7.
1–
29
.5
)
22
6 
(7
7)
22
.5
 (1
7.
1–
29
.5
)
28
 (5
8)
9.
3 
(3
.9
–2
2.
4)
97
 (8
2)
6.
3 
(2
.5
–1
1.
4)
 
Ye
s
0 
(0
)
…
14
7 
(3
7)
34
.6
 (
26
.1
–4
5.
8)
76
 (3
1)
26
.0
 (1
7.
6–
38
.5
)
68
 (2
3)
26
.0
 (1
7.
6–
38
.5
)
7 
(1
5)
39
.0
 (1
6.
2–
93
.7
)
22
 (1
8)
13
.7
 (5
.7
–3
3.
0)
 
U
nk
no
w
n 
a
28
8 
(1
00
)
…
20
 (5
)
71
.6
 (2
9.
8–
17
1.
9)
2 
(1
)
…
0 
(0
)
…
13
 (2
7)
…
0 
(0
)
…
R
ec
en
t 
eq
ui
pm
en
t 
sh
ar
in
g
 
N
o
0 
(0
)
…
67
 (1
7)
15
.8
 (
9.
2–
22
.0
)
13
9 
(5
7)
22
.5
 (1
6.
7–
30
.4
)
23
3 
(7
9)
22
.5
 (1
6.
7–
30
.4
)
0 
(0
)
…
47
 (4
0)
4.
8 
(2
.0
–1
1.
5)
 
Ye
s
0 
(0
)
…
25
7 
(6
5)
28
.1
 (
22
.6
–3
4.
9)
10
3 
(4
2)
24
.9
 (1
7.
8–
34
.8
)
61
 (2
1)
24
.9
 (1
7.
8–
34
.8
)
0 
(0
)
…
1 
(1
)
…
 
U
nk
no
w
na
28
8 
(1
00
)
…
74
 (1
9)
19
.6
 (1
0.
6–
36
.5
)
2 
(1
)
…
0 
(0
)
…
48
 (1
00
)
13
.1
 (7
.0
–2
4.
3)
71
 (6
0)
11
.2
 (6
.2
–2
0.
3)
R
ec
en
t 
op
io
id
 a
go
ni
st
 t
he
ra
py
, i
nc
lu
di
ng
 m
et
ha
do
ne
 a
nd
 b
up
re
no
rp
hi
ne
 
N
o
0 
(0
)
…
34
2 
(8
6)
24
.2
 (1
8.
7–
31
.3
)
16
8 
(6
9)
26
.4
 (2
0.
7–
33
.7
)
15
7 
(5
3)
26
.4
 (2
0.
7–
33
.7
)
23
 (4
8)
19
.9
 (9
.5
–4
1.
6)
44
 (3
7)
8.
4 
(4
.5
–1
5.
6)
 
Ye
s
0 
(0
)
…
50
 (1
3)
11
.8
 (3
.8
–3
6.
6)
75
 (3
1)
15
.3
 (8
.9
–2
6.
3)
13
7 
(4
6)
15
.3
 (8
.9
–2
6.
3)
25
 (5
2)
7.
3 
(2
.3
–2
2.
6)
75
 (6
3)
5.
4 
(2
.2
–1
2.
9)
 
U
nk
no
w
na
28
8 
(1
00
)
…
6 
(2
)
…
1 
(1
)
…
0 
(0
)
…
0 
(0
)
…
0 
(0
)
…
R
ec
en
tly
 o
bt
ai
ne
d 
an
y 
ne
ed
le
s/
sy
rin
ge
s 
fr
om
 s
af
e 
so
ur
ce
b
 
N
o
0 
(0
)
…
47
 (1
2)
6.
9 
(2
.3
–1
8.
4)
21
 (8
)
8.
6 
(2
.8
–2
6.
8)
14
 (5
)
…
0 
(0
)
…
3 
(3
)
…
 
Ye
s
0 
(0
)
…
35
0 
(8
8)
27
.7
 (
22
.8
–3
3.
6)
22
3 
(9
2)
25
.3
 (2
0.
1–
31
.7
)
11
5 
(3
9)
10
.8
 (6
.5
–1
8.
0)
44
 (9
2)
13
.0
 (6
.8
–2
5.
0)
53
 (4
5)
4.
5 
(1
.9
–1
0.
9)
 
U
nk
no
w
n 
a
28
7 
(1
00
)
…
1 
(<
1)
…
0 
(0
)
…
16
5 
(5
6)
24
.9
 (1
9.
1–
32
.5
)
4 
(8
)
13
.7
 (1
.9
–9
7.
4)
63
 (5
3)
11
.3
 (6
.3
–2
0.
5)
In
ci
de
nc
e 
ra
te
s 
ar
e 
sh
ow
n 
as
 IR
 p
er
 1
00
 p
er
so
n-
ye
ar
s 
(9
5%
 c
on
fid
en
ce
 in
te
rv
al
), 
ca
lc
ul
at
ed
 u
si
ng
 t
he
 q
ua
dr
at
ic
 a
pp
ro
xi
m
at
io
n 
to
 t
he
 P
oi
ss
on
 lo
g 
lik
el
ih
oo
d 
fo
r 
th
e 
lo
g-
ra
te
 p
ar
am
et
er
. B
ol
df
ac
e 
va
lu
es
 in
di
ca
te
 s
ig
ni
fic
an
t 
di
ffe
re
nc
e 
at
 P
 <
 .0
5.
A
bb
re
vi
at
io
ns
: H
C
V,
 h
ep
at
iti
s 
C
 v
iru
s;
 H
IV
, h
um
an
 im
m
un
od
efi
ci
en
cy
 v
iru
s;
 IQ
R
, i
nt
er
qu
ar
til
e 
ra
ng
e;
 IR
, i
nc
id
en
ce
 r
at
e;
 P
Y,
 p
er
so
n-
ye
ar
s.
a D
at
a 
no
t 
co
lle
ct
ed
 b
y 
co
ho
rt
 o
r 
no
t 
re
po
rt
ed
 b
y 
pa
rt
ic
ip
an
t;
 t
he
 B
al
tim
or
e 
co
ho
rt
 r
ec
ru
its
 a
nd
 m
on
ito
rs
 y
ou
ng
 p
eo
pl
e 
w
ho
 in
je
ct
 d
ru
gs
 fo
r 
H
C
V
 in
fe
ct
io
n,
 w
ith
 a
 fo
cu
s 
on
 s
er
ol
og
ic
al
 d
at
a 
to
 a
ss
es
s 
th
e 
cl
in
ic
al
 c
ha
ra
ct
er
is
tic
s 
of
 a
cu
te
 in
fe
ct
io
n 
an
d 
re
in
fe
c-
tio
n.
 B
ec
au
se
 r
es
ea
rc
h 
go
al
s 
fo
cu
s 
on
 u
nd
er
st
an
di
ng
 q
ue
st
io
ns
 r
el
at
ed
 t
o 
im
m
un
ol
og
y 
an
d 
vi
ro
lo
gy
, b
eh
av
io
ra
l d
at
a 
w
er
e 
no
t 
sy
st
em
at
ic
al
ly
 c
ol
le
ct
ed
 b
et
w
ee
n 
20
00
 a
nd
 2
01
2.
 T
he
 B
al
tim
or
e 
da
ta
 s
er
ve
r 
w
as
 c
om
pr
om
is
ed
 in
 2
00
5,
 le
ad
in
g 
to
 t
he
 lo
ss
 o
f 
da
ta
 o
n 
ag
e 
an
d 
se
x 
fo
r 
so
m
e 
pa
rt
ic
ip
an
ts
. I
nv
es
tig
at
or
s 
pr
ef
or
m
ed
 g
en
om
e-
w
id
e 
as
so
ci
at
io
n 
st
ud
ie
s 
to
 o
bt
ai
n 
se
x 
fo
r 
pa
rt
ic
ip
an
ts
 w
ho
 a
cq
ui
re
d 
H
C
V
 in
fe
ct
io
n,
 b
ut
 b
ec
au
se
 a
ge
 is
 n
ot
 a
 g
en
et
ic
 t
ra
it,
 a
ge
 in
fo
rm
at
io
n 
w
as
 n
ot
 r
ec
ov
er
ed
.
b S
af
e 
so
ur
ce
 d
efi
ne
d 
as
 n
ee
dl
e 
sy
rin
ge
 p
ro
gr
am
, n
ee
dl
e 
ex
ch
an
ge
 p
ro
gr
am
, c
he
m
is
t/
ph
ar
m
ac
is
t,
 v
en
di
ng
 m
ac
hi
ne
, m
ob
ile
 o
ut
re
ac
h.
Ta
bl
e 
2.
 
Co
nt
in
ue
d
866 • CID 2017:64 (1 April) • Morris et al
for HCV infection decreased an average of 18% per 3 years from 
a high of 31.3/100 PYO in 1994–1997, independent of city, OAT, 
RSS, age, and biological sex. While overall HCV incidence was 
high, we identified differences in infection trends across con-
tinents and cities. High infection rates persisted in the North 
American cities of Baltimore, San Francisco, and Montreal. In 
contrast, incidence was lower in Australian cities (Sydney and 
Melbourne), with Sydney showing a significant reduction in 
the HCV incidence over time. The most significant change was 
observed in Amsterdam, where a sharp decline in HCV inci-
dence was experienced early in the epidemic (1985–1996).
The lower HCV incidence in Amsterdam and Melbourne, 
and the downward trend in Sydney, likely reflect an early and 
sustained implementation of harm reduction services. The 
Netherlands and Australia were global leaders in scaling up 
harm reduction programs to include NSP services. NSP ser-
vices first became available in the Netherlands in 1981; they 
were expanded by the Dutch government in 1984 to include the 
provision of sterile injecting equipment, healthcare, and health 
information and were available at pharmacies and commu-
nity centers and through outreach [17, 18]. Similarly, Australia 
established free and legal government-funded NSP programs in 
the late 1980s. By 1991, 6.3 million syringes were being distrib-
uted annually to an estimated 62 000 regular injectors across 
Australia [19]. Our data show a high (≥80%) level of NSP 
program access across cities. Given the equivalent NSP access 
levels across cities, observed differences in HCV trends likely 
reflect city-specific receptive RSS behaviors. HCV incidence 
Figure 2. Trends in hepatitis C virus (HCV) incidence density (per 100 person-years) across calendar period, by city. Vertical lines represent 95% confidence intervals.
 Abbreviation: HCV, hepatitis C virus. 
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was highest within the North American cities of Baltimore, San 
Francisco, and Montreal, where the prevalence of RSS was con-
sistently >40%. In contrast, the epidemic remained relatively 
stable in cities like Melbourne, where RSS levels were substan-
tially lower. Our findings expand on the results of other stud-
ies showing the relationship between high RSS on increased 
HCV incidence [20–23]. Similar to previous individual human 
immunodeficiency virus (HIV) and HCV incidence studies 
among PWID, we found a relationship between NSP access and 
HCV infection [22–27], which is understandable considering 
that persons seeking NSP services are more likely to experience 
homelessness and inject drugs more frequently than those not 
accessing NSP services.
Overall, HCV incidence rates were lower in Sydney, 
Melbourne, and Amsterdam where OAT uptake was higher than 
in San Francisco. This finding is consistent with recent evidence 
from the United States, Canada, and Australia demonstrating 
the strong protective effect of OAT against HCV infection [13, 
28, 29]. Important differences in OAT policies and subsequent 
OAT availability exist across cities. Compared to the long wait-
ing periods for entry and high-threshold restrictions associated 
with OAT service access in the United States, Australia and the 
Netherlands have lower thresholds for participation and higher 
coverage rates [30, 31]. Our results are consistent with other, 
usually single-site, studies showing the synergistic effect of both 
NSP and OAT on reducing HCV infection among PWID [32], 
an approach that, if sustained with high coverage, has the poten-
tial to also reduce HCV prevalence [33, 34]. Studies show that 
full participation in methadone maintenance therapy (a form of 
OAT) combined with obtaining 100% coverage of syringes from 
sterile distribution sources reduces HCV infection risk by 80% 
compared with no participation [7, 31].
Figure 3. Trends in proportions of self-reported exposures across calendar period, by city. Measurement of selected exposure behaviors collected at enrollment. Proportions 
were calculated for 1985–1990 and 3-year intervals from 1991 to 2011. Note that the Baltimore (Maryland) cohort does not collect survey data. Abbreviations: OAT, opioid 
agonist therapy; RSS, receptive syringe sharing. 
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In Montreal, HCV incidence rates remained high (approx-
imately 20/100 PYO) even though NSP, OAT, and RSS lev-
els were comparable to the lower-HCV-incidence settings of 
Sydney and Melbourne. Montreal’s high prevalence of cocaine 
injection suggests limited impact of OAT on HCV incidence in 
settings where opioids are not the primary drug. When analy-
ses are restricted to Montreal (participants who mainly injected 
heroin/opiates), HCV incidence was significantly lower among 
those reporting recent OAT compared with no recent OAT 
(IRR, 0.4 [95% CI, .2–.8]; data not shown). Given that opioids 
are not the only drug injected, expanded prevention strategies 
to meet the needs of non–opioid users are needed. For exam-
ple, cocaine injectors have larger injecting networks, inject 
more frequently, and engage in riskier injecting practices than 
do opioid injectors [35, 36], and therefore, require increased 
coverage of sterile injecting equipment. Last, given the efficacy 
of OAT in reducing HCV incidence by decreasing injection 
frequency [13, 28, 32], a need remains for efficacious pharma-
cotherapies for cocaine and methamphetamine dependence.
Our study is distinguished from previous work by its interna-
tional scope and its use of participant-level data collected from 
well-characterized cohorts of PWID. However, several limita-
tions exist. First, heterogeneity in cohort protocols for behavio-
ral data collection resulted in an inability to assess time-varying 
predictors of HCV infection. Although this lack of harmoniza-
tion is challenging, we were able to map behavioral trends over 
time by using baseline data on key exposure measures. Differing 
cohort start dates limited our ability to compare cities prior to 
1990. Last, the lack of city-level measures for overall and indi-
vidual harm reduction intervention coverage limited our abil-
ity to assess participant-level differences while controlling for 
city-level variability. Subsequent studies leveraging city-level 
measures of harm reduction and health service access on city-
level HCV infection rates are vital to better understanding how 
structural-level factors, such as changes in access to sterile 
injecting equipment, interact with individual-level factors to 
drive HCV epidemics.
CONCLUSIONS
Contextual differences in the timing and level of harm reduc-
tion programs reflect observed city heterogeneity in behavioral 
patterns and HCV incidence trends. A sustained commitment 
to fund evidence-based harm reduction programs is neces-
sary to maintain low incidence in Amsterdam, Sydney, and 
Melbourne; in contrast, in San Francisco, Baltimore, and 
Montreal, where HCV incidence remains high, an aggressive 
public health approach is urgently needed. In December 2015, 
the US Congress approved the Consolidated Appropriations 
Act 2016, which allows the use of government funds for NSP 
services [37]. For this decision to result in a tangible impact, an 
expanded budget dedicated to NSP services is imperative. NSP 
programs provide a window of opportunity to engage with pop-
ulations who are often underserved by traditional healthcare 
services. Capitalizing on the high (>80%) level of NSP engage-
ment among PWID across cities, scaling up resources for NSP 
services can offer long-term impact. For example, new HCV 
direct-acting antiviral (DAA) therapies offer a highly effective 
tool for controlling the HCV epidemic [38]. Expanding current 
NSP services to inform and introduce DAA treatment both for 
cure and as prevention has the potential to drive down incidence 
[39] while also improving health by resolving infection [40].
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